Publication Name	World Journal of Clinical Oncology
Manuscript ID	21031
Country	United States

Received	2015-06-29 09:44
Peer-Review Started	2015-07-11 11:18
To Make the First Decision	2015-08-16 17:04
Return for Revision	2015-08-21 15:08
Revised	2015-09-09 10:50
Second Decision	2015-11-09 10:38
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2015-11-25 16:14
Articles in Press	2015-11-25 16:14
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-01-18 12:06
Publish the Manuscript Online	2016-01-30 17:42

ISSN	2218-4333 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Editorial
Article Title	Neoadjuvant treatment for resectable pancreatic adenocarcinoma
Manuscript Source	Invited Manuscript
All Author List	John Wong, Naveenraj L Solomon and Chung-Tsen Hsueh
Funding Agency and Grant Number
Corresponding Author	Chung-Tsen Hsueh, MD, PhD, Division of Medical Oncology and Hematology, Department of Internal Medicine, Loma Linda University, 11175 Campus Street, CSP 11015, Loma Linda, CA 92354, United States. chsueh@llu.edu
Key Words	Pancreatic cancer; Resectable pancreatic adenocarcinoma; Neoadjuvant treatment; Biomarkers; Chemotherapy; Surgery
Core Tip	The treatment of resectable pancreatic adenocarcinoma requires multidisciplinary approach and novel strategies including innovative trials to make progress. Data from completed neoadjuvant clinical trials are reviewed, and important ongoing studies are presented. Biomarkers for patient selection and personalized medicine are discussed.
Publish Date	2016-01-30 17:42
Citation	Wong J, Solomon NL, Hsueh CT. Neoadjuvant treatment for resectable pancreatic adenocarcinoma. World J Clin Oncol 2016; 7(1): 1-8
URL	http://www.wjgnet.com/2218-4333/full/v7/i1/1.htm
DOI	http://dx.doi.org/10.5306/wjco.v7.i1.1

Full Article (PDF)	WJCO-7-1.pdf
Full Article (Word)	WJCO-7-1.doc
Manuscript File	21031-Review.docx
Answering Reviewers	21031-Answering reviewers.pdf
Audio Core Tip	21031-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	21031-Conflict-of-interest statement.pdf
Copyright License Agreement	21031-Copyright assignment.pdf
Peer-review Report	21031-Peer-review(s).pdf
Scientific Misconduct Check	21031-Scientific misconduct check.pdf
Scientific Editor Work List	21031-Scientific editor work list.pdf